vTv Therapeutics (VTVT) Q1 2026 Earnings
VTVT·Reported May 13, 2026·Before market open
vTv Therapeutics reported Q1 2026 revenue of $36.8M, beat analyst consensus of $20.0M by $16.8M. Diluted EPS came in at $1.65, beat the $0.34 consensus by $1.31.
Revenue
$36.8Mbeat by $16.8M
Consensus: $20.0MDiluted EPS
$1.65beat by $1.31
Consensus: $0.34
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about vTv Therapeutics's Q1 2026 earnings report.
vTv Therapeutics (VTVT) reported Q1 2026 earnings on May 13, 2026 before market open.
vTv Therapeutics reported revenue of $36.8M and diluted EPS of $1.65 for Q1 2026.
Revenue beat the consensus estimate of $20.0M by $16.8M. EPS beat the consensus estimate of $0.34 by $1.31.
You can read the 8-K earnings release (0001641489-26-000019) and the 10-Q periodic report (0001641489-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.